Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.57 |
| ▸ | MIF | P14174 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5373568 | 1.00 | KMT2A (0.58) | KMT2AMEN1HDAC1HDAC8MIF | |
| SCHEMBL14309048 | 0.92 | KMT2A (0.66) | KMT2AMEN1MIFTP53LMNA | |
| SCHEMBL5376767 | 0.91 | KMT2A (0.62) | KMT2AMEN1HDAC1HDAC8MIF | |
| SCHEMBL5376772 | 0.91 | KMT2A (0.62) | KMT2AMEN1HDAC1HDAC8MIF | |
| SCHEMBL5380386 | 0.86 | POLB (0.66) | KMT2AMEN1HDAC1HDAC8LMNA | |
| SCHEMBL5380390 | 0.86 | POLB (0.66) | KMT2AMEN1HDAC1HDAC8LMNA | |
| SCHEMBL5426560 | 0.82 | MEN1 (0.74) | KMT2AMEN1MIFTP53LMNA | |
| SCHEMBL5373430 | 0.80 | KMT2A (0.70) | KMT2AMEN1MIFTP53LMNA | |
| SCHEMBL3504223 | 0.79 | ALDH1A1 (0.65) | KMT2AMEN1LMNAALDH1A1TSHR | |
| SCHEMBL5372024 | 0.78 | KMT2A (0.71) | KMT2AMEN1MIFTP53LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7262318-B2 | Substituted heteroaryl- and phenylsulfamoyl compounds | PFIZER, INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-20060258723-A1 | Substituted Heteroaryl- and Phenylsulfamoyl Compounds | PFIZER INC | 2006-11-16 | — | — | US | disclosed |
| US-20050228015-A1 | Substituted heteroaryl- and phenylsulfamoyl compounds | PFIZER INC | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228015-A1 | Substituted heteroaryl- and phenylsulfamoyl compounds | PPARA, PPARG, PPARD | KMT2A 3530/4885MEN1 4855/4885HDAC1 416/4885 |
| US-20060258723-A1 | Substituted Heteroaryl- and Phenylsulfamoyl Compounds | PPARG, PPARA, PPARD | KMT2A 3601/4885MEN1 4861/4885HDAC1 396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.